As published on The Straits Times, 28 January 2026

In an exclusive "CEO Insights" feature with The Straits Times, Lucence founder and CEO Dr. Tan Min-Han reveals a bold five-year vision to bring precision health directly to the Singaporean community.

Lucence has established itself as a global leader in cancer detection with over US$80 million in funding and a Mayo Clinic partnership. Now, Dr. Tan is focusing that expertise on the universal challenge of ageing.

Key highlights from the article:

• Polyclinic Integration: Dr. Tan envisions a future where "ageing biomarkers"—detected through a simple blood test—become a standard part of primary care in local polyclinics within five years.

• Beyond Cancer: The technology is evolving to detect early signals of cellular mutation that correlate with major health events like heart attacks and strokes.

• Data-Driven Lifestyle: By marrying AI with blood diagnostics, Lucence aims to provide "high-quality, actionable information" that guides personal choices in diet, sleep, and exercise.

• Global Expansion: Headquartered in Singapore and Palo Alto, Lucence is aggressively scaling, with a 20% headcount growth in the last six months and new expansions into India and Tokyo.

As Singapore moves toward becoming a super-aged society in 2026, Lucence remains committed to bridging the gap between advanced genomic science and everyday wellness, empowering patients to take charge of their own longevity.

Full article here: The Straits Times: Blood tests may soon offer early clues to ageing and health